Brilliant Violet 605™ anti-mouse IL-4 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

Partially purified native mouse IL-4

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Preparation

The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.

Concentration

µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

ICFC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.4 µg per million cells in 100 µl volume. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Excitation Laser

Violet Laser (405 nm)

Application Notes

ELISA^1,2,10,13 or ELISPOT⁵ Capture: The purified 11B11 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated BVD6-24G2 antibody (Cat. No. 504202) as the detecting antibody and recombinant mouse IL-4 (Cat. No. 575609) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture.
Neutralization^1-2,9,12: The 11B11 antibody can neutralize the bioactivity of natural or recombinant IL-4. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IL-4 bioactivity in vivo and in vitro (Cat. No. 504108).
Additional reported applications (for the relevant formats) include: immunoprecipitation¹⁶, immunohistochemical staining of formalin-fixed paraffin-embedded tissue sections⁸ and paraformaldehyde-fixed, saponin-treated frozen tissue sections^6,7, and immunocytochemistry⁴.
Note: For testing mouse IL-4 in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 431101 to 431106) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)

1. Shirai A, et al. 1994. Cytokine 6:329. (ELISA, Neut)
2. Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20. (ELISA, Neut)
3. Assenmacher M, et al. 1994. Eur. J. Immunol. 24:1097.
4. Openshaw P, et al. 1995. J. Exp. Med. 182:1357. (ICC)
5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19. (ELISA Capture)
6. Litton M, et al. 1994. J. Immunol. Methods 175:47. (IHC)
7. Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. (IHC)
8. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
9. Hara M, et al. 2001. J. Immunol. 166:3789. (Neut)
10. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
11. Lawson BR, et al. 2007. J. Immunol. 178:5366.
12. Wang W, et al. 2007. J. Immunol. 178:4885. (Neut)
13. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
14. Ohnmacht C, et al. 2008. Blood 113:2816. PubMed
15. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
16. Zavorotinskaya T, et al. 2003. Mol. Ther. 7:155. (IP)

Product Citations

1. Djokić V, et al. 2019. Front Immunol. 9:2891. PubMed
2. Fang D, et al. 2022. Immunity. 55:639. PubMed
3. Vesin B, et al. 2022. Mol Ther. 30:2984. PubMed
4. Yadava K et al. 2019. Elife. 8 pii: e44821. PubMed
5. Lorentsen KJ, et al. 2018. Nat Commun. 9:1679. PubMed
6. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
7. Li A, et al. 2020. J Virol. 94:00:00. PubMed
8. Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed

RRID

AB_2562101 (BioLegend Cat. No. 504125)
AB_2562101 (BioLegend Cat. No. 504126)

Antigen Details

Structure

Cytokine; 15-19 kD (Mammalian)

Bioactivity

Differentiation of naïve CD4⁺ T cells to the T_H2 type, proliferation/differentiation of activated B cells, expression of class II MHC antigens, and of low affinity IgE receptors in resting B cells

Cell Sources

Mast cells, T cells, bone marrow stromal cells

Cell Targets

B cells, T cells, monocytes, endothelial cells, fibroblasts

Receptors

Heterodimer IL-4Rα (CD124); γ-subunit (CD132) in common with IL-2R, IL-7R, IL-13R, IL-15R

Cell Type

Tregs

Biology Area

Immunology

Molecular Family

Cytokines/Chemokines

Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Boulay J, et al. 1992. Curr. Opin. Immunol. 4:294.
3. Dullens H, et al. 1991. In vivo 5:567.
4. Paul W. 1991. Blood 77:1859.

Regulation

Upregulated by IL-2, platelet activating factor; downregulated by TGF-β

Gene ID

16189 View all products for this Gene ID

UniProt

View information about IL-4 on UniProt.org

Other Formats